ClinicalTrials.gg
CompletedNCT00890981Updated Apr 2, 2014Results posted

A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab

A Phase 3 interventional study of high-resolution peripheral quantitative computed tomography (HR-pQCT) and Dual energy X-ray absorptiometry (DXA) in Low Bone Mass, Low Bone Mineral Density and Osteoporosis, sponsored by Amgen. Completed. Open to female participants. Per ClinicalTrials.gov, last updated 2014-04-02.

Primary conditionOsteoporosis, PostmenopausalRegistry: Bone Diseases, MetabolicReclassifiedWhy we changed it
Registry
Bone Diseases, Metabolic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoporosis, Postmenopausal
Why
  1. The study's listed conditions name Osteoporosis, Postmenopausal, a narrower term within Bone Diseases, Metabolic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
79
Allocation
Not applicable
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.

Enrollment
24th of 31
79 · median 278
Started
2009
with 3 others
Phase 3
17 of 31
1 open now
Registered
6th of 31
by date
Lead sponsor
12 of 31
Amgen

Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 24th largest by enrollment, is one of 4 that started in 2009, is one of 17 in phase 3, and was the 6th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing denosumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

To evaluate the combined effect of denosumab treatment and discontinuation on cortical thickness at the distal radius by High Resolution-Peripheral Quantitative Computed Tomography (HR-pQCT). Participants randomized to either denosumab or placebo in the 20050179 (NCT00293813) study who completed that study (ie, attended an end of study visit) can be included in this study. At least 12 months should have elapsed since the patient's 20050179 end of study visit.

03

Conditions studied

  • Low Bone Mass
  • Low Bone Mineral Density
  • Osteoporosis
  • Postmenopausal Osteoporosis

Browse trials for

04

In context

Osteoporosis, Postmenopausal Reclassified

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

This study's enrollment of 79 is below the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.

Browse Osteoporosis, Postmenopausal studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Osteoporosis, Postmenopausal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Bone Diseases, Metabolic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory, women
  • Randomized to either denosumab or placebo in the 20050179 (NCT00293813) study and completed that study (ie, attended an end of study visit)
  • At least 12 months have elapsed since their end of 20050179 study visit
  • Provide signed

Exclusion criteria

Exclusion Criteria:

  • Subjects who failed to receive both doses of denosumab (or SQ [subcutaneous] placebo) during the 20050179 study
  • Subjects who were randomized to the alendronate arm during the 20050179 study
  • Subjects diagnosed with any of the following conditions following completion of the 20050179 study:
  • Hyperthyroidism
  • Hyperparathyroidism
  • within the last 5 years (except cervical carcinoma in situ or basal cell carcinoma)
  • Any condition that required chronic (greater than three months cumulative and greater than 5 mg/day) therapy
  • Other diseases which affect bone metabolism
  • Self-reported alcohol or drug abuse within the previous 12 months
  • Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written and/or comply with study procedures
  • Received any product other than denosumab in two years before the screening visit.
  • Received > 3 months (or equivalent) of osteoporosis treatment since having completed the 20050179 study.
  • Current use of the following osteoporosis agents: bisphosphonates, calcitonin, fluoride, parathyroid hormone analogue, selective estrogen receptor modulators, systemic oral or transdermal estrogen (except vaginal preparations and estrogen creams which are acceptable), strontium or tibolone.
  • Currently enrolled in or has not yet completed at least 1 month since ending other investigational device or drug trial(s) (other than Amgen trial 20080287), or subject is receiving other investigational agent(s).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
79 participants (actual)

Study arms

  • Other
    Arm 1

    Participants who were randomized to either denosumab or placebo in Study 20050179 and at least 12 months had elapsed from their 20050179 end-of-study visit had dual energy X-ray absorptiometry (DXA) of the forearm and HR-pQCT of the tibia and radius on Day 1 of this study. No study drug was administered.

    Procedure: high-resolution peripheral quantitative computed tomography (HR-pQCT) · Procedure: Dual energy X-ray absorptiometry (DXA) · Biological: Denosumab · Drug: Placebo

Interventions

  • Procedurehigh-resolution peripheral quantitative computed tomography (HR-pQCT)

    Bone densitometry and microarchitecture assessments of the distal radius and the distal tibia by HR-pQCT on Day 1.

  • ProcedureDual energy X-ray absorptiometry (DXA)

    Bone densitometry assessments of the forearm by DXA on day 1.

  • BiologicalDenosumab

    Denosumab 60 mg subcutaneously every 6 months in the previous study

  • DrugPlacebo

    Placebo to denosumab subcutaneously every 6 months in the previous study

07

What researchers measure

Primary outcomes

  1. Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT

    Percent change from the 20050179 Baseline in cortical thickness at the distal radius as determined by high-resolution peripheral quantitative computed tomography (HR-pQCT) at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.

    Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.

Secondary outcomes

  1. Percent Change From the Parent Study Baseline in Total Bone Mineral Density (BMD) at the Distal Radius by HR-pQCT

    Percent change from the 20050179 Baseline in total BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.

    Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.

  2. Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Radius by HR-pQCT

    Percent change from the 20050179 Baseline in cortical BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.

    Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.

  3. Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Radius by HR-pQCT

    Percent change from the 20050179 Baseline in trabecular BMD at the distal radius as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.

    Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.

  4. Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Tibia by HR-pQCT

    Percent change from the 20050179 Baseline in cortical thickness at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.

    Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.

  5. Percent Change From the Parent Study Baseline in Total BMD at the Distal Tibia by HR-pQCT

    Percent change from the 20050179 Baseline in total BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.

    Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.

  6. Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Tibia by HR-pQCT

    Percent change from the 20050179 Baseline in cortical BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.

    Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.

  7. Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Tibia by HR-pQCT

    Percent change from the 20050179 Baseline in trabecular BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.

    Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.

  8. Percent Change of Distal 1/3 Radius BMD From the Parent Study Baseline by DXA

    Percent change of distal 1/3 radius BMD from the 20050179 Baseline as determined by dual energy X-ray absorptiometry (DXA) at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.

    Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.

  9. Percent Change of Ultradistal Radius BMD From the Parent Study Baseline by DXA

    Percent change of ultradistal radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since last the subcutaneous dose of denosumab or placebo in study 20050179.

    Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.

  10. Percent Change of Total Radius BMD From the Parent Study Baseline by DXA

    Percent change of total radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.

    Time frame: Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.

  11. Actual Value of Serum Type I C-telopeptide

    Actual value of Serum Type I C-telopeptide measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).

    Time frame: Day 1

  12. Actual Value of Procollagen Type 1 N-terminal Peptide

    Actual value of Type 1 N-terminal Peptide as measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).

    Time frame: Day 1

08

Results

Posted Jul 28, 2011

Participant flow

The first subject enrolled on 14-JUL-2009. The last subject enrolled on 12-MAY-2010

Participant flow — Overall Study
MilestonePrevious Placebo Treatment GroupPrevious Denosumab Treatment Group
Started3940
Completed3940
Not completed00

Outcome measures

PrimaryPercent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT

Percent change from the 20050179 Baseline in cortical thickness at the distal radius as determined by high-resolution peripheral quantitative computed tomography (HR-pQCT) at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.

Time frame:
Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Reported as:
Least squares mean · Percent change
Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT
Percent changePrevious Placebo Treatment GroupPrevious Denosumab Treatment Group
Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT-5.5 (-8.3 to -2.8)-1.8 (-4.8 to 1.2)
Statistical analysis
  • Previous Placebo Treatment Group vs Previous Denosumab Treatment Group · ANCOVA · p = 0.0766 · Mean difference (final values): 3.7 · 95% CI -0.4 to 7.8
SecondaryPercent Change From the Parent Study Baseline in Total Bone Mineral Density (BMD) at the Distal Radius by HR-pQCT

Percent change from the 20050179 Baseline in total BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.

Time frame:
Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Reported as:
Least squares mean · Percent change
Percent Change From the Parent Study Baseline in Total Bone Mineral Density (BMD) at the Distal Radius by HR-pQCT
Percent changePrevious Placebo Treatment GroupPrevious Denosumab Treatment Group
Percent Change From the Parent Study Baseline in Total Bone Mineral Density (BMD) at the Distal Radius by HR-pQCT-1.2 (-2.6 to 0.2)0.3 (-1.2 to 1.7)
Statistical analysis
  • Previous Placebo Treatment Group vs Previous Denosumab Treatment Group · ANCOVA · p = 0.1648 · Mean difference (final values): 1.5 · 95% CI -0.6 to 3.5
SecondaryPercent Change From the Parent Study Baseline in Cortical BMD at the Distal Radius by HR-pQCT

Percent change from the 20050179 Baseline in cortical BMD at the distal radius as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.

Time frame:
Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Reported as:
Least squares mean · Percent change
Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Radius by HR-pQCT
Percent changePrevious Placebo Treatment GroupPrevious Denosumab Treatment Group
Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Radius by HR-pQCT-1.0 (-1.7 to -0.3)-0.0 (-0.8 to 0.8)
Statistical analysis
  • Previous Placebo Treatment Group vs Previous Denosumab Treatment Group · ANCOVA · p = 0.0228 · Mean difference (final values): 0.9 · 95% CI 0.1 to 1.7
SecondaryPercent Change From the Parent Study Baseline in Trabecular BMD at the Distal Radius by HR-pQCT

Percent change from the 20050179 Baseline in trabecular BMD at the distal radius as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.

Time frame:
Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Reported as:
Least squares mean · Percent change
Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Radius by HR-pQCT
Percent changePrevious Placebo Treatment GroupPrevious Denosumab Treatment Group
Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Radius by HR-pQCT5.1 (2.3 to 8.0)5.9 (2.8 to 9.0)
Statistical analysis
  • Previous Placebo Treatment Group vs Previous Denosumab Treatment Group · ANCOVA · p = 0.6560 · Mean difference (final values): 0.7 · 95% CI -2.5 to 4.0
SecondaryPercent Change From the Parent Study Baseline in Cortical Thickness at the Distal Tibia by HR-pQCT

Percent change from the 20050179 Baseline in cortical thickness at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.

Time frame:
Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Reported as:
Least squares mean · Percent change
Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Tibia by HR-pQCT
Percent changePrevious Placebo Treatment GroupPrevious Denosumab Treatment Group
Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Tibia by HR-pQCT-6.4 (-7.8 to -5.1)-4.6 (-5.9 to -3.3)
Statistical analysis
  • Previous Placebo Treatment Group vs Previous Denosumab Treatment Group · ANCOVA · p = 0.0594 · Mean difference (final values): 1.8 · 95% CI -0.1 to 3.7
SecondaryPercent Change From the Parent Study Baseline in Total BMD at the Distal Tibia by HR-pQCT

Percent change from the 20050179 Baseline in total BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.

Time frame:
Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Reported as:
Least squares mean · Percent change
Percent Change From the Parent Study Baseline in Total BMD at the Distal Tibia by HR-pQCT
Percent changePrevious Placebo Treatment GroupPrevious Denosumab Treatment Group
Percent Change From the Parent Study Baseline in Total BMD at the Distal Tibia by HR-pQCT-1.6 (-2.8 to -0.4)1.0 (-0.2 to 2.2)
Statistical analysis
  • Previous Placebo Treatment Group vs Previous Denosumab Treatment Group · ANCOVA · p = 0.0032 · Mean difference (final values): 2.6 · 95% CI 0.9 to 4.3
SecondaryPercent Change From the Parent Study Baseline in Cortical BMD at the Distal Tibia by HR-pQCT

Percent change from the 20050179 Baseline in cortical BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.

Time frame:
Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Reported as:
Least squares mean · Percent change
Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Tibia by HR-pQCT
Percent changePrevious Placebo Treatment GroupPrevious Denosumab Treatment Group
Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Tibia by HR-pQCT-1.0 (-1.7 to -0.3)-0.6 (-1.4 to 0.2)
Statistical analysis
  • Previous Placebo Treatment Group vs Previous Denosumab Treatment Group · ANCOVA · p = 0.2897 · Mean difference (final values): 0.4 · 95% CI -0.4 to 1.2
SecondaryPercent Change From the Parent Study Baseline in Trabecular BMD at the Distal Tibia by HR-pQCT

Percent change from the 20050179 Baseline in trabecular BMD at the distal tibia as determined by HR-pQCT at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.

Time frame:
Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Reported as:
Least squares mean · Percent change
Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Tibia by HR-pQCT
Percent changePrevious Placebo Treatment GroupPrevious Denosumab Treatment Group
Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Tibia by HR-pQCT2.9 (1.0 to 4.9)6.8 (4.9 to 8.8)
Statistical analysis
  • Previous Placebo Treatment Group vs Previous Denosumab Treatment Group · ANCOVA · p = 0.0067 · Mean difference (final values): 3.9 · 95% CI 1.1 to 6.7
SecondaryPercent Change of Distal 1/3 Radius BMD From the Parent Study Baseline by DXA

Percent change of distal 1/3 radius BMD from the 20050179 Baseline as determined by dual energy X-ray absorptiometry (DXA) at an average of 32 months since last subcutaneous dose of denosumab or placebo in study 20050179.

Time frame:
Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Reported as:
Least squares mean · Percent change
Percent Change of Distal 1/3 Radius BMD From the Parent Study Baseline by DXA
Percent changePrevious Placebo Treatment GroupPrevious Denosumab Treatment Group
Percent Change of Distal 1/3 Radius BMD From the Parent Study Baseline by DXA-2.0 (-3.3 to -0.8)0.0 (-1.2 to 1.2)
Statistical analysis
  • Previous Placebo Treatment Group vs Previous Denosumab Treatment Group · ANCOVA · p = 0.0184 · Mean difference (final values): 2.1 · 95% CI 0.4 to 3.8
SecondaryPercent Change of Ultradistal Radius BMD From the Parent Study Baseline by DXA

Percent change of ultradistal radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since last the subcutaneous dose of denosumab or placebo in study 20050179.

Time frame:
Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Reported as:
Least squares mean · Percent change
Percent Change of Ultradistal Radius BMD From the Parent Study Baseline by DXA
Percent changePrevious Placebo Treatment GroupPrevious Denosumab Treatment Group
Percent Change of Ultradistal Radius BMD From the Parent Study Baseline by DXA-3.5 (-4.9 to -2.2)-1.9 (-3.3 to -0.6)
Statistical analysis
  • Previous Placebo Treatment Group vs Previous Denosumab Treatment Group · ANCOVA · p = 0.0911 · Mean difference (final values): 1.6 · 95% CI -0.3 to 3.5
SecondaryPercent Change of Total Radius BMD From the Parent Study Baseline by DXA

Percent change of total radius BMD from the 20050179 Baseline as determined by DXA at an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179.

Time frame:
Baseline of Study 20050179 and Day 1 of this study. Study 20050179 duration was up to 12 months and the median time since completion of Study 20050179 was 32 months.
Reported as:
Least squares mean · Percent change
Percent Change of Total Radius BMD From the Parent Study Baseline by DXA
Percent changePrevious Placebo Treatment GroupPrevious Denosumab Treatment Group
Percent Change of Total Radius BMD From the Parent Study Baseline by DXA-3.0 (-4.0 to -2.0)-0.9 (-1.9 to 0.1)
Statistical analysis
  • Previous Placebo Treatment Group vs Previous Denosumab Treatment Group · ANCOVA · p = 0.0035 · Mean difference (final values): 2.1 · 95% CI 0.7 to 3.5
SecondaryActual Value of Serum Type I C-telopeptide

Actual value of Serum Type I C-telopeptide measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).

Time frame:
Day 1
Reported as:
Least squares mean · ng/mL
Actual Value of Serum Type I C-telopeptide
ng/mLPrevious Placebo Treatment GroupPrevious Denosumab Treatment Group
Actual Value of Serum Type I C-telopeptide0.6 (0.5 to 0.6)0.7 (0.6 to 0.7)
Statistical analysis
  • Previous Placebo Treatment Group vs Previous Denosumab Treatment Group · ANCOVA · p = 0.0591 · Ratio of denosumab to placebo: 1.1 · 95% CI 1.0 to 1.3
SecondaryActual Value of Procollagen Type 1 N-terminal Peptide

Actual value of Type 1 N-terminal Peptide as measured from blood samples taken on Day 1 (an average of 32 months since the last subcutaneous dose of denosumab or placebo in study 20050179).

Time frame:
Day 1
Reported as:
Least squares mean · µg/L
Actual Value of Procollagen Type 1 N-terminal Peptide
µg/LPrevious Placebo Treatment GroupPrevious Denosumab Treatment Group
Actual Value of Procollagen Type 1 N-terminal Peptide49.8 (45.6 to 54.3)58.9 (54.1 to 64.2)
Statistical analysis
  • Previous Placebo Treatment Group vs Previous Denosumab Treatment Group · ANCOVA · p = 0.0079 · Ratio of denosumab to placebo: 1.2 · 95% CI 1.0 to 1.3

Adverse events

Collected over AEs (serious only) were collected after informed consent and through 30 days after the study procedures, maximum time on study was 44 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Previous Placebo Treatment Group—0/39 (0%)—
Previous Denosumab Treatment Group—0/40 (0%)—

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Previous Placebo Treatment GroupPrevious Denosumab Treatment GroupTotal
Mean63.9 ± 5.863.4 ± 6.563.7 ± 6.1
Sex: Female, Male
Sex: Female, Male(Participants)Previous Placebo Treatment GroupPrevious Denosumab Treatment GroupTotal
Female394079
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Previous Placebo Treatment GroupPrevious Denosumab Treatment GroupTotal
Number394079
Months since last dose in 20050179
Months since last dose in 20050179(Months)Previous Placebo Treatment GroupPrevious Denosumab Treatment GroupTotal
Mean32.1 ± 2.532.2 ± 2.732.1 ± 2.6
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • concept.747 Treatment/discontinuation on wrist.Journal-004521;
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Jun 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2009
First posted
Apr 30, 2009
Start
Jul 2009
Primary completionActual
Jun 2010
CompletionActual
Aug 2010
Results first posted
Jul 28, 2011
Last update
Apr 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00890981
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 30, 2009
Start date
Jul 2009
Primary completion
Jun 2010
Completion
Aug 2010
Results posted
Jul 28, 2011
Last update
Apr 2, 2014

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion